These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

837 related items for PubMed ID: 17110217

  • 1. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
    Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS, Dutasteride Alopecia Research Team.
    J Am Acad Dermatol; 2006 Dec; 55(6):1014-23. PubMed ID: 17110217
    [Abstract] [Full Text] [Related]

  • 2. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
    Gubelin Harcha W, Barboza Martínez J, Tsai TF, Katsuoka K, Kawashima M, Tsuboi R, Barnes A, Ferron-Brady G, Chetty D.
    J Am Acad Dermatol; 2014 Mar; 70(3):489-498.e3. PubMed ID: 24411083
    [Abstract] [Full Text] [Related]

  • 3. Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss.
    Roberts JL, Fiedler V, Imperato-McGinley J, Whiting D, Olsen E, Shupack J, Stough D, DeVillez R, Rietschel R, Savin R, Bergfeld W, Swinehart J, Funicella T, Hordinsky M, Lowe N, Katz I, Lucky A, Drake L, Price VH, Weiss D, Whitmore E, Millikan L, Muller S, Gencheff C.
    J Am Acad Dermatol; 1999 Oct; 41(4):555-63. PubMed ID: 10495375
    [Abstract] [Full Text] [Related]

  • 4. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study.
    Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY, Ro BI, Cho HK, Sim WY, Lew BL, Lee WS, Park HY, Hong SP, Ji JH.
    J Am Acad Dermatol; 2010 Aug; 63(2):252-8. PubMed ID: 20605255
    [Abstract] [Full Text] [Related]

  • 5. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
    Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC, Thiboutot DM, Lowe N, Jacobson C, Whiting D, Stieglitz S, Kraus SJ, Griffin EI, Weiss D, Carrington P, Gencheff C, Cole GW, Pariser DM, Epstein ES, Tanaka W, Dallob A, Vandormael K, Geissler L, Waldstreicher J.
    J Am Acad Dermatol; 1999 Oct; 41(4):550-4. PubMed ID: 10495374
    [Abstract] [Full Text] [Related]

  • 6. Finasteride in the treatment of Japanese men with male pattern hair loss.
    Kawashima M, Hayashi N, Igarashi A, Kitahara H, Maeguchi M, Mizuno A, Murata Y, Nogita T, Toda K, Tsuboi R, Ueki R, Yamada M, Yamazaki M, Matsuda T, Natsumeda Y, Takahashi K, Harada S.
    Eur J Dermatol; 2004 Oct; 14(4):247-54. PubMed ID: 15319158
    [Abstract] [Full Text] [Related]

  • 7. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia.
    Finasteride Male Pattern Hair Loss Study Group.
    Eur J Dermatol; 2002 Oct; 12(1):38-49. PubMed ID: 11809594
    [Abstract] [Full Text] [Related]

  • 8. Dutasteride improves male pattern hair loss in a randomized study in identical twins.
    Stough D.
    J Cosmet Dermatol; 2007 Mar; 6(1):9-13. PubMed ID: 17348989
    [Abstract] [Full Text] [Related]

  • 9. Effective treatment of female androgenic alopecia with dutasteride.
    Olszewska M, Rudnicka L.
    J Drugs Dermatol; 2005 Mar; 4(5):637-40. PubMed ID: 16167423
    [Abstract] [Full Text] [Related]

  • 10. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS.
    Prostate; 2004 Feb 01; 58(2):130-44. PubMed ID: 14716738
    [Abstract] [Full Text] [Related]

  • 11. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.
    Price VH, Roberts JL, Hordinsky M, Olsen EA, Savin R, Bergfeld W, Fiedler V, Lucky A, Whiting DA, Pappas F, Culbertson J, Kotey P, Meehan A, Waldstreicher J.
    J Am Acad Dermatol; 2000 Nov 01; 43(5 Pt 1):768-76. PubMed ID: 11050579
    [Abstract] [Full Text] [Related]

  • 12. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT.
    Clin Cancer Res; 2006 Jul 01; 12(13):4072-9. PubMed ID: 16818707
    [Abstract] [Full Text] [Related]

  • 13. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
    Musquera M, Fleshner NE, Finelli A, Zlotta AR.
    Expert Rev Anticancer Ther; 2008 Jul 01; 8(7):1073-9. PubMed ID: 18588452
    [Abstract] [Full Text] [Related]

  • 14. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
    Festuccia C, Gravina GL, Muzi P, Pomante R, Angelucci A, Vicentini C, Bologna M.
    J Urol; 2008 Jul 01; 180(1):367-72. PubMed ID: 18499161
    [Abstract] [Full Text] [Related]

  • 15. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
    Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S.
    J Clin Endocrinol Metab; 2004 May 01; 89(5):2179-84. PubMed ID: 15126539
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration.
    Ryu HK, Kim KM, Yoo EA, Sim WY, Chung BC.
    Br J Dermatol; 2006 Apr 01; 154(4):730-4. PubMed ID: 16536818
    [Abstract] [Full Text] [Related]

  • 17. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
    Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, Lazier CB, Rittmaster RS.
    J Urol; 2004 Sep 01; 172(3):915-9. PubMed ID: 15310997
    [Abstract] [Full Text] [Related]

  • 18. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H, Lan O, Poulain JE, Comenducci A.
    Prog Urol; 2005 Dec 01; 15(6):1090-5. PubMed ID: 16429658
    [Abstract] [Full Text] [Related]

  • 19. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS.
    Urology; 2004 Sep 01; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [Abstract] [Full Text] [Related]

  • 20. Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old.
    Camacho FM, García-Hernández MJ, Fernández-Crehuet JL.
    Br J Dermatol; 2008 May 01; 158(5):1121-4. PubMed ID: 18363752
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.